China Regenerative Medicine International Limited

SEHK:8158 Rapporto sulle azioni

Cap. di mercato: HK$130.8m

China Regenerative Medicine International Gestione

Gestione criteri di controllo 3/4

China Regenerative Medicine International Il CEO è Chuang Wang, nominato in Jul2020, e ha un mandato di 4.33 anni. la retribuzione annua totale è HK$ 1.46M, composta da 85.3% di stipendio e 14.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 24.28% delle azioni della società, per un valore di HK$ 31.77M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 3.9 anni.

Informazioni chiave

Chuang Wang

Amministratore delegato

HK$1.5m

Compenso totale

Percentuale dello stipendio del CEO85.3%
Mandato del CEO4.3yrs
Proprietà del CEO24.3%
Durata media del management4.3yrs
Durata media del Consiglio di amministrazione3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 32% Pounding

Mar 05
Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 32% Pounding

China Regenerative Medicine International Limited's (HKG:8158) Price Is Right But Growth Is Lacking After Shares Rocket 57%

Jan 04
China Regenerative Medicine International Limited's (HKG:8158) Price Is Right But Growth Is Lacking After Shares Rocket 57%

These 4 Measures Indicate That China Regenerative Medicine International (HKG:8158) Is Using Debt Extensively

Sep 21
These 4 Measures Indicate That China Regenerative Medicine International (HKG:8158) Is Using Debt Extensively

China Regenerative Medicine International Limited (HKG:8158) May Have Run Too Fast Too Soon With Recent 31% Price Plummet

Jun 11
China Regenerative Medicine International Limited (HKG:8158) May Have Run Too Fast Too Soon With Recent 31% Price Plummet

Is China Regenerative Medicine International (HKG:8158) A Risky Investment?

May 22
Is China Regenerative Medicine International (HKG:8158) A Risky Investment?

Is China Regenerative Medicine International (HKG:8158) A Risky Investment?

Apr 13
Is China Regenerative Medicine International (HKG:8158) A Risky Investment?

Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?

Sep 22
Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?

Introducing China Regenerative Medicine International (HKG:8158), The Stock That Zoomed 142% In The Last Year

Mar 16
Introducing China Regenerative Medicine International (HKG:8158), The Stock That Zoomed 142% In The Last Year

What Is The Ownership Structure Like For China Regenerative Medicine International Limited (HKG:8158)?

Feb 08
What Is The Ownership Structure Like For China Regenerative Medicine International Limited (HKG:8158)?

Trade Alert: The CEO & Executive Chairman Of China Regenerative Medicine International Limited (HKG:8158), Chuang Wang, Has Just Spent HK$55m Buying 428% More Shares

Dec 15
Trade Alert: The CEO & Executive Chairman Of China Regenerative Medicine International Limited (HKG:8158), Chuang Wang, Has Just Spent HK$55m Buying 428% More Shares

Don't Ignore The Fact That This Insider Just Sold Some Shares In China Regenerative Medicine International Limited (HKG:8158)

Nov 25
Don't Ignore The Fact That This Insider Just Sold Some Shares In China Regenerative Medicine International Limited (HKG:8158)

Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?

Nov 24
Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chuang Wang rispetto agli utili di China Regenerative Medicine International?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-HK$104m

Mar 31 2024n/an/a

-HK$101m

Dec 31 2023HK$1mHK$1m

-HK$108m

Sep 30 2023n/an/a

HK$677k

Jun 30 2023n/an/a

HK$15m

Mar 31 2023n/an/a

HK$5m

Dec 31 2022HK$1mn/a

HK$5m

Sep 30 2022n/an/a

HK$31m

Jun 30 2022n/an/a

HK$26m

Mar 31 2022n/an/a

HK$49m

Dec 31 2021HK$1mn/a

HK$52m

Sep 30 2021n/an/a

-HK$95m

Jun 30 2021n/an/a

-HK$82m

Mar 31 2021n/an/a

-HK$105m

Dec 31 2020HK$1mn/a

-HK$120m

Sep 30 2020n/an/a

-HK$201m

Jun 30 2020n/an/a

-HK$237m

Mar 31 2020n/an/a

-HK$239m

Dec 31 2019HK$245kHK$245k

-HK$264m

Compensazione vs Mercato: La retribuzione totale di Chuang ($USD 188.03K ) è circa la media per le aziende di dimensioni simili nel mercato Hong Kong ($USD 233.89K ).

Compensazione vs guadagni: La retribuzione di Chuang è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Chuang Wang (45 yo)

4.3yrs

Mandato

HK$1,461,000

Compensazione

Mr. Chuang Wang has been Executive Chairman at China Regenerative Medicine International Limited since October 18, 2019 and serves as its Chief Executive Officer since July 9, 2020 and also serves as its C...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Chuang Wang
CEO, Executive Chairman & Compliance Officer4.3yrsHK$1.46m24.28%
HK$ 31.8m
Po Tin Wong
CFO & Company Secretary2.2yrsNessun datoNessun dato
Jinnan Zhang
Chief Technology Officer6.2yrsNessun datoNessun dato

4.3yrs

Durata media

45yo

Età media

Gestione esperta: Il team dirigenziale di 8158 è considerato esperto (durata media dell'incarico 4.3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Chuang Wang
CEO, Executive Chairman & Compliance Officer5.1yrsHK$1.46m24.28%
HK$ 31.8m
Man Fai Leung
Independent Non-Executive Director2.9yrsHK$120.00kNessun dato
Chunyu Huo
Independent Non-Executive Director4.8yrsHK$120.00kNessun dato
Ming Liu
Independent Non-Executive Director2.9yrsHK$120.00kNessun dato

3.9yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 8158 sono considerati esperti (durata media dell'incarico 3.9 anni).